Get started
Author

Melissa Bersanelli

Observed names: Bersanelli M, Bersanelli Melissa, Bersanelli, Melissa, M Bersanelli, M. Bersanelli, MELISSA BERSANELLI
ORCID: 0000-0002-6527-6281
Observed ORCID: 0000-0002-6527-6281
OpenAlex ID: A5012176145
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable
2019 · Alessio Cortellini, Melissa Bersanelli, et al. · Journal for ImmunoTherapy of Cancer · 413
PDF
Controversies About COVID-19 and Anticancer Treatment with Immune Checkpoint Inhibitors
2020 · Melissa Bersanelli · Immunotherapy · 213
PDF
Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study
2019 · Alessio Cortellini, Sebastiano Buti, et al. · The Oncologist · 205
PDF
Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients
2019 · Alessio Cortellini, Rita Chiari, et al. · Clinical Lung Cancer · 178
L718Q Mutation as New Mechanism of Acquired Resistance to AZD9291 in EGFR -Mutated NSCLC
2016 · Melissa Bersanelli, Roberta Minari, et al. · Journal of Thoracic Oncology · 167
PDF
Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer
2021 · Caroline A. Nebhan, Alessio Cortellini, et al. · JAMA Oncology · 161
Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events
2020 · Alessio Cortellini, Melissa Bersanelli, et al. · European Journal of Cancer · 127
Risk of recurrent venous thromboembolism and major hemorrhage in cancer‐associated incidental pulmonary embolism among treated and untreated patients: a pooled analysis of 926 patients
2015 · T. van der Hulle, P.L. den Exter, et al. · Journal of Thrombosis and Haemostasis · 124
Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index
2020 · Sebastiano Buti, Melissa Bersanelli, et al. · European Journal of Cancer · 115
Soluble PD-L1 and Circulating CD8+PD-1+ and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients
2020 · G. Mazzaschi, R. Minari, et al. · Lung Cancer · 111
Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study)
2021 · Sara Elena Rebuzzi, Alessio Signori, et al. · Therapeutic Advances in Medical Oncology · 98
PDF
Chemotherapy in metastatic renal cell carcinoma today? A systematic review
2013 · Sebastiano Buti, Melissa Bersanelli, et al. · Anti-Cancer Drugs · 93
Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes
2020 · Alessio Cortellini, Alex Friedlaender, et al. · Clinical Lung Cancer · 86
PDF
Validation of a new prognostic model to easily predict outcome in renal cell carcinoma: the GRANT score applied to the ASSURE trial population
2017 · S. Buti, M. Puligandla, et al. · Annals of Oncology · 85
The gut microbiome and efficacy of cancer immunotherapy
2021 · Giandomenico Roviello, Luigi Francesco Iannone, et al. · Pharmacology & Therapeutics · 76
Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
2023 · Alessio Cortellini, Antonio D'Alessio, et al. · Clinical Cancer Research · 75
PDF
Sex Hormones and Hormone Therapy during COVID-19 Pandemic: Implications for Patients with Cancer
2020 · Carlo Cattrini, Melissa Bersanelli, et al. · Cancers · 75
PDF
Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) Consortium
2023 · Talal El Zarif, Amin H. Nassar, et al. · Journal of Clinical Oncology · 74
PDF
Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours
2023 · Ciro Celsa, Giuseppe Cabibbo, et al. · Journal of Hepatology · 72
PDF
Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study
2020 · Olga Nigro, Graziella Pinotti, et al. · European Journal of Cancer · 72
PDF
The Prognostic Role of High Blood Cholesterol in Advanced Cancer Patients Treated With Immune Checkpoint Inhibitors
2020 · Fabiana Perrone, Roberta Minari, et al. · Journal of Immunotherapy · 68
From targeting the tumor to targeting the immune system: Transversal challenges in oncology with the inhibition of the PD-1/PD-L1 axis
2017 · Melissa Bersanelli, Sebastiano Buti · World Journal of Clinical Oncology · 64
PDF
Everolimus in the management of metastatic renal cell carcinoma: an evidence-based review of its place in therapy
2016 · Sebastiano Buti, Alessandro Leonetti, et al. · Core evidence · 64
PDF
A systematic review on the emerging association between the occurrence of immune-related adverse events and clinical outcomes with checkpoint inhibitors in advanced cancer patients
2019 · Alessio Cortellini, Sebastiano Buti, et al. · Seminars in Oncology · 62
Patient performance status and cancer immunotherapy efficacy: a meta-analysis
2018 · Melissa Bersanelli, Matteo Brighenti, et al. · Medical Oncology · 62
Works count: 403
Citation count: 4,885
H-index: 34
I10-index: 103
Year
Topic
Type